Treatment, Outcomes, and Challenges of Newly Diagnosed AML in Children and Adolescents
作者： Robert J. Arceci
DOI: 10.1007/978-1-59745-322-6_17
关键词:
摘要: Acute myeloid leukemia (AML) in children encompasses a distinctive set of diseases with special considerations related to age, drug metabolism, and both short- long-term sequelae. This chapter will emphasize inherited syndromes that predispose leukemogenesis, development secondary AML, the roles dose intensification stem cell transplantation ongoing improvement cure rates. The importance risk stratification design clinical trials, based on cytogenetic molecular characteristics, is critical optimizing balance between curability, quality life, minimization sequelae for AML.
springer.com
sci-hub.st 参考文章(227)
WG Woods, N Kobrinsky, JD Buckley, JW Lee, J Sanders, S Neudorf, S Gold, DR Barnard, J DeSwarte, K Dusenbery, D Kalousek, DC Arthur, BJ Lange, Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group Blood. ,vol. 87, pp. 4979- 4989 ,(1996) , 10.1182/BLOOD.V87.12.4979.BLOODJOURNAL87124979
C J Harrison, I M Hann, B E S Gibson, D K W Webb, MRC trials in childhood acute myeloid leukaemia. Annals of Hematology. ,(2004) , 10.1007/S00277-004-0850-2
G. V. Dahl, D. K. Kalwinsky, J. Mirro, A. T. Look, A Comparison of Cytokinetically Based Versus Intensive Chemotherapy for Childhood Acute Myelogenous Leukemia Acute Leukemias. ,vol. 30, pp. 83- 87 ,(1987) , 10.1007/978-3-642-71213-5_14
RO Dillman, RB Davis, MR Green, RB Weiss, AJ Gottlieb, S Caplan, S Kopel, H Preisler, OR McIntyre, C Schiffer, A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood. ,vol. 78, pp. 2520- 2526 ,(1991) , 10.1182/BLOOD.V78.10.2520.2520
M. Linet, J. G. Gurney, L. A. G. Ries, M. A. Smith, T. Tamra, G. R. Bunin, J. L. Young, Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995.. ,(1999)
U. Jaeger, B. Kainz, Monitoring minimal residual disease in AML: the right time for real time. Annals of Hematology. ,vol. 82, pp. 139- 147 ,(2003) , 10.1007/S00277-002-0601-1
Thuret I, Nelken B, Esperou-Bourdeau H, Leblanc T, Bordigoni P, Baruchel A, Leverger G, Schaison G, Vannier Jp, Bergeron C, Michel G, Perel Y, Landman-Parker J, Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Bone Marrow Transplantation. ,vol. 17, pp. 191- 196 ,(1996)
J.F. San Miguel, A. Martı́nez, A. Macedo, M.B. Vidriales, C. López-Berges, M. González, D. Caballero, M.A. Garcı́a-Marcos, F. Ramos, J. Fernández-Calvo, M.J. Calmuntia, J. Diaz-Mediavilla, A. Orfao, Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients Blood. ,vol. 90, pp. 2465- 2470 ,(1997) , 10.1182/BLOOD.V90.6.2465
S C Raimondi, Y Ravindranath, H J Weinstein, M V Gresik, F G Behm, C P Steuber, A J Carroll, M N Chang, Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood. ,vol. 94, pp. 3707- 3716 ,(1999) , 10.1182/BLOOD.V94.11.3707
Mel Greaves, Pre-natal origins of childhood leukemia. Reviews in Clinical and Experimental Hematology. ,vol. 7, pp. 233- 245 ,(2003)